Objectives
- List available HCV direct acting antivirals (DAAs) available for HCV therapy in 2016
- Describe appropriate HCV DAA therapies for HCV genotypes 1, 2, and 3
- Evaluate the potential for DAA drug-drug interactions, particularly with HIV antiretroviral therapy.
Presented by:
Cody Chastain, MD
Assistant Professor, Viral Hepatitis Program
Vanderbilt University School of Medicine, Division of Infectious Diseases
Browse more